甲基化
DNA甲基化
结直肠癌
癌症研究
发起人
去甲基化
生物
体内
细胞凋亡
癌症
分子生物学
基因表达
DNA
基因
遗传学
作者
Qin Wang,Lei Dai,Yuan Wang,Jie Deng,Yi Lin,Qingnan Wang,Chao Fang,Zida Ma,Huiling Wang,Gang Shi,Lin Cheng,Yi Liu,Shuang Chen,Junshu Li,Zhexu Dong,Xiaolan Su,Lie Yang,Shuang Zhang,Ming Jiang,Meijuan Huang
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2019-02-13
卷期号:448: 132-143
被引量:38
标识
DOI:10.1016/j.canlet.2019.01.040
摘要
SARI (suppressor of activator protein 1, regulated by IFN) functions as a tumour suppressor and is inactivated in various cancers. However, the mechanism underlying SARI inactivation in cancer remains elusive. In this study, we detected a high level of DNA methylation of the SARI promoter and an inverse correlation between SARI promoter methylation and expression in malignant tissues from patients with colon cancer. Furthermore, we found that the SARI promoter methylation status is a prognostic indicator for patients with colon cancer. A dCas9-multiGCN4/scFv-TET1CD-sgRNA-based SARI-targeted demethylation system (dCas9-multiGCN4/scFv-TET1CD-sgSARI) was constructed to precisely and specifically demethylate regions of SARI; this system resulted in the substantial activation of SARI expression. Further in vitro and in vivo data confirmed that dCas9-multiGCN4/scFv-TET1CD-sgSARI exerts anti-tumour effects by regulating tumour proliferation, apoptosis, and angiogenesis. Collectively, specific demethylation of the SARI promoter and restoration of endogenous SARI expression by dCas9-multiGCN4/scFv-TET1CD-SARI have therapeutic applications for colon cancer and perhaps for other cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI